Chapter 246-883 WAC

PHARMACEUTICAL—SALES REQUIRING PRESCRIPTIONS

WAC 246-883-020 Identification of legend drugs for purposes of chapter 69.41 RCW.

WAC 246-883-025 Introductory trade or stock packages.

WAC 246-883-030 Ephedrine prescription restrictions.

WAC 246-883-040 Regulated steroids.

WAC 246-883-050 Theophylline prescription restrictions.

WAC 246-883-020 Identification of legend drugs for purposes of chapter 69.41 RCW. (1) In accordance with chapter 69.41 RCW, the board of pharmacy finds that those drugs which have been determined by the Food and Drug Administration, under the Federal Food, Drug and Cosmetic Act, to require a prescription under federal law should also be classified as legend drugs under state law because of their toxicity or potential for harmful effect, the methods of their use and the collateral safeguards necessary to their use, indicate that they are only safe for use under the supervision of a practitioner.

(2) For the purposes of chapter 69.41 RCW, legend drugs are drugs which have been designated as legend drugs under federal law and are listed as such in the 2009 edition of the Drug Topics Red Book. Copies of the list of legend drugs as contained in the Drug Topics Red Book are available for public inspection at the headquarters office of the State Board of Pharmacy, 310 Israel Road S.E., P.O. BOX 47863, Olympia, Washington 98504-7863. To obtain copies of this list from the department, interested persons must submit a written request, indicating which format they wish to receive, and payment of the actual cost of the text or CD, including shipping and handling charges from the publisher. Requestors may also contact the publisher directly to obtain copies. The department takes no responsibility for periodic updates or online access. Arrangements for periodic updates or online access must be made directly with the publisher.

(3) There may be changes in the marketing status of drugs after the publication of the above reference. Upon application of a manufacturer or distributor, the board may grant authority for the over the counter distribution of certain drugs which had been designated as legend drugs in this reference. These determinations will be made after public hearing and will be published as an amendment to this chapter.

TRADE NAME  
1. AMESAC capsule  
   (Russ)  
   25 mg. ephedrine HCL

2. AZMA AID tablet  
   (Various, eg Purepac)  
   12 mg. ephedrine

3. BRONC-EASE PLUS  
   (Natur-Pharma)  
   25 mg. ephedrine HCL

4. BRONCHODILATOR AND EXPECTORANT  
   (PDK Labs)  
   25 mg. ephedrine HCL

5. BRONITIN tablet  
   (Whitehall)  
   24 mg. ephedrine HCL

6. BRONKAID tablet  
   (Breon)  
   24 mg. ephedrine sulfate

7. BRONKOLIXER  
   (Sterling Winthrop)  
   12 mg. ephedrine

8. BRONKOTABS tablet  
   (Breon)  
   24 mg. ephedrine sulfate

[Statutory Authority: RCW 18.64.005. WSR 92-09-072 (Order 266B), § 246-883-025, filed 4/14/92, effective 5/15/92.]


WAC 246-883-025 Introductory trade or stock packages. Introductory trade or stock packages may be distributed by registered drug manufacturers to licensed pharmacies under the following conditions:

1. The package shall be invoiced by the drug manufacturer as a no charge sale.

2. The product shall be distributed by the manufacturer to the pharmacy by mail or common carrier.

3. The drug's package shall not be marked as a sample or with any other labeling that is inconsistent with the claim that the manufacturer intended the package for sale.

4. The manufacturer shall be limited to distributing one introductory package of each dosage strength of a product on a one-time basis to a pharmacy in order to familiarize and assure that a company's new product will be available in pharmacies. The quantity shall not be larger than one hundred solid dosage units or sixteen liquid ounces.

[Statutory Authority: RCW 18.64.005. WSR 92-09-072 (Order 266B), § 246-883-025, filed 4/14/92, effective 5/15/92.]

WAC 246-883-030 Ephedrine prescription restrictions. (1) The board of pharmacy, pursuant to RCW 69.41.-075, hereby identifies ephedrine, or any of its salts in a solid or aqueous form normally intended for oral administration, in any quantity, as a legend drug subject to the restrictions of RCW 69.41.030.

(2) The following products containing ephedrine or its salts in the amount of 25 mg. or less per solid dosage unit or per 5 ml. of liquid forms in combination with other ingredients in therapeutic amounts are exempt from subsection (1) of this section:

TRADE NAME  
1. AMESAC capsule  
   (Russ)  
   25 mg. ephedrine HCL

2. AZMA AID tablet  
   (Various, eg Purepac)  
   12 mg. ephedrine

3. BRONC-EASE PLUS  
   (Natur-Pharma)  
   25 mg. ephedrine HCL

4. BRONCHODILATOR AND EXPECTORANT  
   (PDK Labs)  
   25 mg. ephedrine HCL

5. BRONITIN tablet  
   (Whitehall)  
   24 mg. ephedrine HCL

6. BRONKAID tablet  
   (Breon)  
   24 mg. ephedrine sulfate

7. BRONKOLIXER  
   (Sterling Winthrop)  
   12 mg. ephedrine

8. BRONKOTABS tablet  
   (Breon)  
   24 mg. ephedrine sulfate

[Ch. 246-883 WAC p. 1]
Regulated steroids. The board finds that the following drugs shall be classified as steroids for the purposes of RCW 69.41.310. The drugs designated shall include the following and any synthetic derivatives or any isomer, ester, salt, or derivative of the following that act in the same manner on the human body from the attached list:

1. Anabolicum
2. Anadrol
3. Anatrofin
4. Anavar
5. Androxon
6. Andriol
7. Android
8. bolandiol
9. bolasterone
10. boldenone
11. boldenone undecylenate
12. bolenol
13. Bolfortan
14. bolmantalate
15. Cheque
16. chlorotestosterone
17. clostebol
18. Deca Durabolin
19. dehydrochloromethyl-testosterone
20. Delatestyl
21. Dianabol
22. Dihydrolone
23. dihydrotestosterone
24. dimethazine
25. Drive
26. Drolban
27. drostanolone
28. Durabolin
29. Durateston
30. Equipoise
31. Esiicone
32. ethylestrenol
33. Exoboline
34. Finaject
35. Fluoxymesterone
36. formebolone
37. Halotestin
38. Halostein
39. Hombreol
40. Iontanyl
41. Laurabolin
42. Lipodex
43. Maxibolin
44. mesterolone
45. metanabol
46. methenolone acetate
47. methenolone enanthate
48. methandienone
49. methandranone
50. methandriol
51. methandrostenolone
52. methyltestosterone
53. mibolerone
54. Myagen
55. Nandrolin
nandrolone
nandrolone decanoate
nandrolone cyclotate
nandrolone phenpropionate
Nelavar
Nerobol
Nilevar
nisterime acetate
Norbolethone
Nor-Diethylin
norethandrolone
Normethazine
Omnifin
Oxandrolone
oxymesterone
oxymetholone
Parabolan
Permastril
pizotyline
Primobolone/Primobolan depot
Primotestin/Primotestin depot
Proviron
Quinalone
Quinabolone
Restandol
silandrone
Sostanon
Spectriol
stanolone
stanozolol
stenbolone acetate
Stromba
Sustanon
tes-10
tes-20
tes-30
Teslac
testolactone
testosterone
testosterone cypionate
testosterone enanthate
testosterone ketolaurate
testosterone phenylacetate
testosterone propionate
testosterone undecanoate
Thiomucase
tibolone
trenbolone
trenbolone acetate
trestolone acetate
Trophobolene
Winstrol

[Statutory Authority: RCW 18.64.005 and 69.41.075. WSR 92-09-070 (Order 264B), § 246-883-050, filed 4/14/92, effective 5/15/92.]

WAC 246-883-050 Theophylline prescription restrictions. The board of pharmacy, pursuant to RCW 69.41.075, hereby identifies theophylline, or any of its salts in a solid or liquid form normally intended for oral administration in any quantity, as a legend drug subject to the restrictions of RCW 69.41.030. Provided, products containing 130 mg or less of theophylline per solid dosage unit or 130 mg or less per 5 ml of liquid forms, shall not be considered a legend drug and where the product contains other recognized therapeutic ingredients, may be sold or distributed without a prescription. Products with theophylline as the only active ingredient are identified as legend drugs.

[Statutory Authority: RCW 18.64.005. WSR 92-12-035 (Order 277B), § 246-883-040, filed 5/28/92, effective 6/28/92. Statutory Authority: RCW 18.64.005 and chapter 18.64A RCW. WSR 91-18-057 (Order 191B), recodified as § 246-883-040, filed 8/30/91, effective 9/30/91. Statutory Authority: RCW 18.64.005. WSR 89-22-048, § 360-32-060, filed 10/30/89, effective 11/30/89.]